SVB Leerink reiterated coverage on Immatics with a new price target

3/17/21 11:52:56 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

SVB Leerink reiterated coverage of Immatics with a rating of Outperform and set a new price target of $26.00 from $17.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$IMTX

Date	Price Target	Rating	Analyst
5/28/2025	$10.00	Buy	Deutsche Bank
10/7/2024	$19.00	Overweight	Piper Sandler
11/2/2023		Overweight	Cantor Fitzgerald
3/31/2023	$12.00	Buy	Mizuho
3/24/2023	$16.00	Buy	Bryan Garnier
7/15/2021	$26.00 → $27.00	Outperform	SVB Leerink